CL2008003358A1 - Hidratos cristalinos de n-(4((2s,3r)-3-((s)-3-(4-fluorofenil)-3-hidroxipropil)-2-(4-metoxifenil)4-oxoazetidin-1-il)bencil)-n-((2s,3r,4r,5r)-2,3,4,5,6-pentahidroxihexil)dodecandiamida; procedimiento de preparacion de dicho compuesto; composiicon farmaceutica que lo comprende; y uso para tratar trastornos del metabolismo de lipidos. - Google Patents

Hidratos cristalinos de n-(4((2s,3r)-3-((s)-3-(4-fluorofenil)-3-hidroxipropil)-2-(4-metoxifenil)4-oxoazetidin-1-il)bencil)-n-((2s,3r,4r,5r)-2,3,4,5,6-pentahidroxihexil)dodecandiamida; procedimiento de preparacion de dicho compuesto; composiicon farmaceutica que lo comprende; y uso para tratar trastornos del metabolismo de lipidos.

Info

Publication number
CL2008003358A1
CL2008003358A1 CL2008003358A CL2008003358A CL2008003358A1 CL 2008003358 A1 CL2008003358 A1 CL 2008003358A1 CL 2008003358 A CL2008003358 A CL 2008003358A CL 2008003358 A CL2008003358 A CL 2008003358A CL 2008003358 A1 CL2008003358 A1 CL 2008003358A1
Authority
CL
Chile
Prior art keywords
dodecandiamide
oxoazetidin
pentahydroxyhexyl
fluorophenyl
methoxyphenyl
Prior art date
Application number
CL2008003358A
Other languages
English (en)
Spanish (es)
Inventor
Theodor Andreas Wollmann
Regina Duffy
Frank Cullmann
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40386121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008003358(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of CL2008003358A1 publication Critical patent/CL2008003358A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CL2008003358A 2007-11-13 2008-11-11 Hidratos cristalinos de n-(4((2s,3r)-3-((s)-3-(4-fluorofenil)-3-hidroxipropil)-2-(4-metoxifenil)4-oxoazetidin-1-il)bencil)-n-((2s,3r,4r,5r)-2,3,4,5,6-pentahidroxihexil)dodecandiamida; procedimiento de preparacion de dicho compuesto; composiicon farmaceutica que lo comprende; y uso para tratar trastornos del metabolismo de lipidos. CL2008003358A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007054497A DE102007054497B3 (de) 2007-11-13 2007-11-13 Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung

Publications (1)

Publication Number Publication Date
CL2008003358A1 true CL2008003358A1 (es) 2009-06-26

Family

ID=40386121

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003358A CL2008003358A1 (es) 2007-11-13 2008-11-11 Hidratos cristalinos de n-(4((2s,3r)-3-((s)-3-(4-fluorofenil)-3-hidroxipropil)-2-(4-metoxifenil)4-oxoazetidin-1-il)bencil)-n-((2s,3r,4r,5r)-2,3,4,5,6-pentahidroxihexil)dodecandiamida; procedimiento de preparacion de dicho compuesto; composiicon farmaceutica que lo comprende; y uso para tratar trastornos del metabolismo de lipidos.

Country Status (11)

Country Link
US (1) US8003636B2 (https=)
EP (1) EP2220040B1 (https=)
JP (1) JP5401463B2 (https=)
AR (1) AR069305A1 (https=)
CL (1) CL2008003358A1 (https=)
DE (2) DE102007054497B3 (https=)
PA (1) PA8803701A1 (https=)
PE (1) PE20091165A1 (https=)
TW (1) TW200936566A (https=)
UY (1) UY31469A1 (https=)
WO (1) WO2009062619A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8486926B2 (en) * 2006-11-17 2013-07-16 Harbor Therapeutics, Inc. Steroid tetrol solid state forms
US20080319221A1 (en) * 2007-06-22 2008-12-25 Bernd Junker Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
EA018974B9 (ru) * 2008-02-05 2014-04-30 Харбор Терапьютикс, Инк. Твердые лекарственные формы
DK2273994T3 (en) * 2008-04-03 2016-02-01 Neurmedix Inc PHARMACEUTICAL FORMS OF A MEDICINE
EP3954688A1 (en) * 2012-12-22 2022-02-16 Kbp Biosciences Pte. Ltd. Crystal forms of compound used as mineralocorticoid receptor antagonist and methods for their preparation
US10064871B2 (en) 2014-01-22 2018-09-04 Biomimetix Jv, Llc Methods of treating skin disorders
US10080759B2 (en) 2014-01-22 2018-09-25 Duke University Methods of treating pruritus

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0124317B1 (en) * 1983-04-27 1990-04-11 Ici Americas Inc. Proline derivatives
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
PT877750E (pt) 1995-10-31 2002-09-30 Schering Corp 2-azetidinonas substituidas por acucar uteis como agentes hipocolesterolemiantes
US6225310B1 (en) * 1996-01-17 2001-05-01 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
AU727775B2 (en) 1996-01-17 2000-12-21 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
US5739321A (en) 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
IL127296A (en) 1996-12-31 2003-01-12 Reddy Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
PL338013A1 (en) 1997-07-16 2000-09-25 Novo Nordisk As Derivatives of condensed 1,2,4-thiadiazine, their production and application
CO4970713A1 (es) * 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
WO1999046262A1 (en) 1998-03-12 1999-09-16 Teijin Limited Benzofurylpyrone derivatives
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
DE69922043T2 (de) 1998-12-07 2005-11-24 Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. Glp-1 analoge
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
WO2000063703A1 (en) 1999-04-16 2000-10-26 Schering Corporation Use of azetidinone compounds
EP1177176B1 (en) 1999-04-28 2006-04-19 Aventis Pharma Deutschland GmbH Tri-aryl acid derivatives as ppar receptor ligands
NZ515086A (en) 1999-04-28 2003-10-31 Aventis Pharma Gmbh Di-aryl acid derivatives as PPAR receptor ligands
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
DE60029446T2 (de) 1999-06-18 2007-02-08 Merck & Co., Inc. Arylthiazolidindione und aryloxazolidindion-derivate
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
BR0012752A (pt) 1999-07-29 2002-04-02 Lilly Co Eli Benzofuril piperazinas e benzofuril homopiperazinas: agonistas de serotonina
HUP0202472A3 (en) 1999-09-01 2005-03-29 Aventis Pharma Gmbh Sulfonyl carboxiamide derivatives, method for their production and their use as medicaments
PE20011010A1 (es) 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
WO2001062266A2 (en) 2000-02-25 2001-08-30 Novo Nordisk A/S Use of dpp-iv inhibitors for the treatment of diabetes
AU5257401A (en) * 2000-04-28 2001-11-12 Asahi Chemical Ind Novel bicyclic compounds
DE60115227T2 (de) 2000-05-11 2006-08-24 Bristol-Myers Squibb Co. Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
WO2002008188A1 (en) * 2000-07-25 2002-01-31 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
HUP0004741A2 (hu) 2000-11-28 2002-12-28 Sanofi-Synthelabo Kémiai eljárás tiazolszármazékok előállítására és új intermedier
AU2002231688A1 (en) 2000-12-21 2002-07-01 Sanofi-Aventis Deutschland Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
IL156552A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
HRP20030498A2 (en) * 2000-12-21 2005-04-30 Aventis Pharma Deutschland Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
TWI291957B (en) 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
GB0113233D0 (en) 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical compounds
DE10139416A1 (de) 2001-08-17 2003-03-06 Aventis Pharma Gmbh Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
HRP20040199A2 (en) * 2001-08-31 2005-04-30 Aventis Pharma Deutschland Gmbh Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar activators
US6884812B2 (en) * 2001-08-31 2005-04-26 Aventis Pharma Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
DE10215907A1 (de) 2002-04-11 2003-11-06 Aventis Pharma Gmbh Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
JPWO2003097064A1 (ja) 2002-05-17 2005-09-15 協和醗酵工業株式会社 糖尿病治療剤
DE10227508A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US7671047B2 (en) * 2002-06-19 2010-03-02 Sanofi-Aventis Deutschland Gmbh Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7176193B2 (en) * 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
DE10227507A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US7176194B2 (en) * 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
DE10227506A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
RS20050019A (sr) 2002-07-12 2007-09-21 Sanofi - Aventis Pharma Deutschland Gmbh., Heterociklično supstituisani benzoilkarbamidi,postupak za njihovu proizvodnju i njihova primena kao leka
DE10314610A1 (de) 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
CN100472485C (zh) 2003-04-25 2009-03-25 松下电器产业株式会社 服务器及服务器的处理方法
JP2005015434A (ja) 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
RU2006103797A (ru) 2003-07-09 2006-07-27 Форбз Меди-Тек Инк. (Ca) Новые соединения и композиции, содержащие стерины и/или станолы и ингибиторы биосинтеза холестерина, и их применение для лечения или предупреждения различных заболеваний и состояний
WO2005005477A2 (en) 2003-07-11 2005-01-20 Novo Nordisk A/S Stabilised insulin compositions
US20070072812A1 (en) 2003-08-25 2007-03-29 Microbia, Inc. Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones
EP1660446A2 (en) 2003-08-28 2006-05-31 Microbia, Inc. Tethered dimers and trimers of 1,4-diphenylazetidn-2-ones
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
EP1522541A1 (en) 2003-10-07 2005-04-13 Lipideon Biotechnology AG Novel hypocholesterolemic compounds
EP1682117A1 (en) 2003-10-30 2006-07-26 Merck & Co., Inc. 2-azetidinones as anti-hypercholesterolemic agents
WO2005042692A2 (en) 2003-10-31 2005-05-12 Forbes Medi-Tech Inc. A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors
AU2004288822A1 (en) 2003-11-10 2005-05-26 Microbia, Inc. 4-Biarylyl-1-phenylazetidin-2-ones
GB0329778D0 (en) 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
CN100471835C (zh) 2003-12-23 2009-03-25 默克公司 抗高胆固醇血症化合物
EP1699759B1 (en) 2003-12-23 2010-10-20 AstraZeneca AB Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
PL1711184T3 (pl) 2004-01-06 2007-12-31 Janssen Pharmaceutica Nv Pochodne (3-okso-3,4-dihydrochinoksalin-2-yloamino)benzamidu i związki pokrewne jako inhibitory fosforylazy glikogenowej do leczenia cukrzycy i otyłości
DE102004006325A1 (de) 2004-02-10 2005-08-25 Bayer Healthcare Ag Tetrahydrobenzo[d]azepin-2-on-Derivate und ihre Verwendung
NZ548817A (en) 2004-03-10 2009-04-30 Janssen Pharmaceutica Nv MTP inhibiting aryl piperidines or piperazines substituted with 5-membered heterocycles
EP1736467A4 (en) 2004-04-06 2009-07-01 Dainippon Sumitomo Pharma Co NEW SULFONIC ACID AMID DERIVATIVE
WO2005097076A2 (en) 2004-04-09 2005-10-20 Smithkline Beecham Corporation Low dose pharmaceutical products
DE102004025072A1 (de) * 2004-05-21 2005-12-15 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Diphenyl-azetidinon-Derivaten
FR2871463B1 (fr) 2004-06-11 2006-09-22 Merck Sante Soc Par Actions Si Derives a structure aroyl-o-piperidine, leurs procedes de preparation, les compositions pharmaceutiques qui les contiennent et leurs applications en therapeutique
AU2005267436A1 (en) 2004-06-24 2006-02-02 Eli Lilly And Company Compounds and methods for treating dyslipidemia
WO2006017257A2 (en) 2004-07-12 2006-02-16 Phenomix Corporation Azetidinone derivatives
FR2873368B1 (fr) 2004-07-26 2008-01-04 Merck Sante Soc Par Actions Si Derives de guanidine et leurs utilisations en therapeutique
FR2873694B1 (fr) 2004-07-27 2006-12-08 Merck Sante Soc Par Actions Si Nouveaux aza-indoles inhibiteurs de la mtp et apob
EP1794159B1 (en) 2004-09-11 2012-08-01 Sanofi-Aventis Deutschland GmbH 7-azaindoles and their use as ppar agonists
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
US8030273B2 (en) 2004-10-07 2011-10-04 Novo Nordisk A/S Protracted exendin-4 compounds
WO2006045564A1 (en) 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
JP2008517029A (ja) 2004-10-22 2008-05-22 スミスクライン・ビーチャム・コーポレイション Ｈｍ７４ａ受容体活性を有するキサンチン誘導体
WO2006059744A1 (ja) 2004-11-30 2006-06-08 Nippon Chemiphar Co., Ltd. ペルオキシソーム増殖剤活性化受容体δの活性化剤
AU2005324127A1 (en) 2004-12-18 2006-07-13 Bayer Healthcare Ag (5S) -3-[(S)-fluoro (4-trifluoromethylphenyl) methyl]-5,6,7,8-tetrahydroquinoline-5-ol derivatives and use thereof as CETP inhibitors
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
JP5065908B2 (ja) 2004-12-24 2012-11-07 プロシディオン・リミテッド Ｇタンパク質結合受容体作動薬
EP1838311A1 (en) 2004-12-24 2007-10-03 Prosidion Limited G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes
WO2006073973A2 (en) 2004-12-31 2006-07-13 Reddy Us Therapeutics, Inc. Novel benzylamine derivatives as cetp inhibitors
DE102005000666B3 (de) 2005-01-04 2006-10-05 Sanofi-Aventis Deutschland Gmbh Sulfonylpyrrolidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU2006210503B2 (en) 2005-02-03 2009-09-03 Irm Llc Compounds and compositions as PPAR modulators
US20090005321A1 (en) 2005-02-09 2009-01-01 Microbia, Inc. Phenylazetidinone Derivatives
FR2883000B1 (fr) 2005-03-14 2007-06-01 Merck Sante Soc Par Actions Si Derives de trifluoromethylbenzamide et leurs utilisations en therapeutique
US20090186834A1 (en) 2005-03-24 2009-07-23 Microbia, Inc. Diphenylheterocycle cholesterol absorption inhibitors
AU2006236939A1 (en) 2005-04-13 2006-10-26 Merck Sharp & Dohme Corp. Niacin receptor agonists, compositions containing such compounds and methods of treatment
WO2006116499A1 (en) 2005-04-26 2006-11-02 Microbia, Inc. 4-biarylyl-1-phenylazetidin-2-one glucuronide derivatives for hypercholesterolemia
US20090131395A1 (en) 2005-05-05 2009-05-21 Microbia, Inc. Biphenylazetidinone cholesterol absorption inhibitors
EP1883419A4 (en) 2005-05-06 2010-08-04 Bayer Pharmaceuticals Corp GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR PHARMACOLOGICAL USES
EP1879860A2 (en) 2005-05-10 2008-01-23 Microbia Inc. 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia
CA2608075A1 (en) 2005-05-11 2006-11-16 Microbia, Inc. Processes for production of phenolic 4-biphenylylazetidin-2-ones
PT1881850E (pt) 2005-05-13 2010-11-26 Lilly Co Eli Compostos peguilados de glp-1
BRPI0610133A2 (pt) 2005-05-17 2010-06-01 Schering Corp heterociclos como agonistas de receptor de ácido nicotìnico para o tratamento de dislipidemia
EA200702614A1 (ru) 2005-05-25 2008-04-28 Майкробиа, Инк. Способы получения 4-(бифенилил)азетидин-2-оналкилфосфиновых кислот
EP1893222A4 (en) 2005-06-15 2010-07-07 Merck Sharp & Dohme ANTI-HYPERCHOLESTERINAMIC COMPOUNDS
UY29607A1 (es) 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
AR057383A1 (es) 2005-06-22 2007-12-05 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
AR056866A1 (es) 2005-06-22 2007-10-31 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, una formulacion farmaceutica y un proceso de preparacion del compuesto
AR054482A1 (es) 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR057380A1 (es) 2005-06-22 2007-11-28 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
MY148538A (en) 2005-06-22 2013-04-30 Astrazeneca Ab Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
US7067689B1 (en) * 2005-07-08 2006-06-27 Microbia, Inc. Process for production of pentahydroxyhexylcarbamoyl alkanoic acids
JP2007022943A (ja) 2005-07-13 2007-02-01 Dai Ichi Seiyaku Co Ltd スクアレン合成酵素阻害薬
DE102005033100B3 (de) 2005-07-15 2007-01-25 Sanofi-Aventis Deutschland Gmbh Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, diese Verbindung enthaltene Arzneimittel und Verfahren zu deren Herstellung
DE102005033099A1 (de) 2005-07-15 2007-01-18 Sanofi-Aventis Deutschland Gmbh Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindung enthaltende Arzneimittel und dessen Verwendung
WO2007015744A1 (en) 2005-07-21 2007-02-08 Incyte Corporation Disubstituted thienyl compounds and their use as pharmaceuticals
BRPI0615145A2 (pt) 2005-08-10 2009-11-03 Smithkline Beecham Corp derivados de xantina como agonistas hm74a seletivos
GB0516462D0 (en) 2005-08-10 2005-09-14 Smithkline Beecham Corp Novel compounds
US20090258862A1 (en) 2005-08-29 2009-10-15 Colletti Steven L Niacin receptor agonists, compositions containing such compounds and methods of treatment
CA2621227A1 (en) 2005-08-31 2007-03-08 Astellas Pharma Inc. Thiazole derivative
AU2006299092A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl-(1,2,4)-oxadiazol-5-one derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals
WO2007041494A2 (en) 2005-09-30 2007-04-12 Merck & Co., Inc. Cholesteryl ester transfer protein inhibitors
DE102005055726A1 (de) * 2005-11-23 2007-08-30 Sanofi-Aventis Deutschland Gmbh Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US20080319221A1 (en) 2007-06-22 2008-12-25 Bernd Junker Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
US20080319218A1 (en) * 2007-06-22 2008-12-25 Andreas Haubrich Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate
WO2009112203A1 (de) * 2008-03-14 2009-09-17 Sanofi-Aventis Deutschland Gmbh Verfahren zur herstellung eines diphenylazetidinons

Also Published As

Publication number Publication date
DE102007054497B3 (de) 2009-07-23
UY31469A1 (es) 2009-07-17
AR069305A1 (es) 2010-01-13
US20090203578A1 (en) 2009-08-13
PE20091165A1 (es) 2009-08-31
TW200936566A (en) 2009-09-01
JP5401463B2 (ja) 2014-01-29
EP2220040B1 (de) 2013-01-16
JP2011503127A (ja) 2011-01-27
PA8803701A1 (es) 2009-06-23
WO2009062619A1 (de) 2009-05-22
US8003636B2 (en) 2011-08-23
EP2220040A1 (de) 2010-08-25
DE102007063671A1 (de) 2009-06-25

Similar Documents

Publication Publication Date Title
CL2008003358A1 (es) Hidratos cristalinos de n-(4((2s,3r)-3-((s)-3-(4-fluorofenil)-3-hidroxipropil)-2-(4-metoxifenil)4-oxoazetidin-1-il)bencil)-n-((2s,3r,4r,5r)-2,3,4,5,6-pentahidroxihexil)dodecandiamida; procedimiento de preparacion de dicho compuesto; composiicon farmaceutica que lo comprende; y uso para tratar trastornos del metabolismo de lipidos.
BRPI0714671B8 (pt) Preparação de (2r,3r)-3-(3-metoxifenil)-n,n,2-trimetilpentanamina e compostos intermediários
NO20076447L (no) Bicykliske derivater som modulatorer av ionekanaler
NO20071742L (no) Kinazoliner som er nyttige som modulatorer av ionekanaler
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
CL2008001465A1 (es) Compuestos derivados de [2,1,3]benzoxadiazol-5-carboxamidas, moduladores de los receptores ampa; composiciones farmacéuticas; y su uso en el tratamiento de afecciones hipoglutamatérgicas, trastornos cognitivos, enfermedad de parkinson, adhd, síndrome de rett, depresión respiratoria, síndrome x frágil y enfermedad de alzheimer.
WO2007075895A3 (en) Heterocyclic derivatives as modulators of ion channels
NO20090157L (no) Tienpyrimidiner anvendelige som modulatorer av ionekanaler
WO2010002956A3 (en) Heterocyclic derivatives as modulators of ion channels
BRPI0715531A2 (pt) Composto, composição farmacêutica, método para o tratamento de uma enfermidade e/ou distúrbio metabólico, processo para a preparação de compostos e uso do composto
EP2114925A4 (en) AZETIDINE ANALOGUE AIS NUCLEOSIDASE AND PHOSPHORYLASE HEMMER
CL2009000967A1 (es) Compuesto 4-ciclobutil-n-((2s,5r)-5-hidroxi-2-adamantil)-2-morfolin-4-ilpiridin-5-carboxamida, inhibidor de la enzima 11betahsd1; composicion farmaceutica que lo comprende; y su uso en un procedimiento de tratamiento profilactico o terapeutico de un animal de sangre caliente.
EA200970967A1 (ru) Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip)
NO20080141L (no) Indanderivater som modulatorer av ionekanaler
CL2009000464A1 (es) Compuestos derivados de 3-(n-(azetidin-3-il)metanosulfonilamino)benzamida, actuan en los receptores cannabinoides cb1; procedimiento para prepararlos; composici0n farmaceutica y su uso para tratar o prevenir trastornos psiquiatricos, trastornos cognitivos, enfermedades neurodegenerativas, trastornos del metabolismo, dolor.
NO20075111L (no) Farmasoytisk sammensetning
IL205697A0 (en) 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazole-2-yl)benzenesulfon-amide derivatives, compositions comprising the same and uses thereof
CL2008002247A1 (es) Compuestos derivados de fenil amida; proceso de preparacion; composicion farmaceutica que los contiene; y su uso en la preparacion de medicamentos para el tratamiento de trastornos del sueno, narcolepsia y trastornos psiquiatricos, entre otros.
BR112012008650A2 (pt) n-((1r,2s,5r)-5-(terc-butilamino)-2-((s)-3-(7-terc-butilpirazolo[1,5-a][1,3,5]tria-zin-4-ilamino)-2-oxopirrolidin-1-il)cicloexil)acetamida, um modulador dual de atividade de receptor de quimiocina, formas cristalinas e processos
ATE540036T1 (de) Heterocyclische derivate als ionenkanalmodulatoren
EA200901237A1 (ru) Применение димирацетама при лечении хронической боли
CL2012000097A1 (es) Compuestos derivados de 3-fenoximetilpirrolidina, inhibidores de la recaptacion de serotonina-norepinefrina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos del dolor, depresion, entre otros.
BRPI0617655A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica
WO2007058989A3 (en) Quinazolines useful as modulators of voltage gated ion channels
CO6341474A2 (es) Formas solidas de (1r,2s,3r)-1-(2-isoxazol-3-il)-1h-imidazol-4-il) butano-1,2,3,4-tetraol y metodos para su uso